The Group has three reportable segments, as discussed below, which are based on information provided to the Board of Directors, which is deemed to be the Group's chief operating decision maker. Several operating segments which have similar economic characteristics have been aggregated into the reporting segments.
The European Pharmaceuticals Segment comprises Dechra Veterinary Products EU and Dechra Pharmaceuticals Manufacturing. This Segment operates internationally and manufactures and markets Companion Animal, Equine and Food producing Animal Products. This Segment also includes third party manufacturing sales.
The North American (NA) Pharmaceuticals Segment consists of Dechra Veterinary Products US and Dechra Veterinary Products Canada, which sell Companion Animal and Equine Products into those territories. The Segment expanded during the prior year with the acquisition of PSPC Inc.'s manufacturing unit based in Melbourne, Florida, and during the current year with the opening of the Canadian subsidiary.
The Pharmaceuticals Research and Development Segment includes all of the Group's pharmaceutical research and development activities. From a Board perspective, this Segment has no revenue income.
Reconciliations of reportable segment revenues, profit or loss and liabilities and other material items:
|Revenue by segment|
|European Pharmaceuticals — total||168,665||172,449|
|— inter segment||(32)||(35)|
|NA Pharmaceuticals — total||34,870||21,215|
|— inter segment||(23)||(58)|
|Operating profit/(loss) by segment|
|Pharmaceuticals Research and Development||(8,671)||(8,248)|
|Segment operating profit||49,996||46,748|
|Corporate and other unallocated costs||(5,645)||(4,580)|
|Underlying operating profit||44,351||42,168|
|Amortisation of acquired intangibles||(17,871)||(16,543)|
|Total operating profit||25,980||24,996|
|Profit before taxation — continuing operations||25,806||21,442|
|Total liabilities by segment|
|Pharmaceuticals Research and Development||(710)||(633)|
|Corporate loans and revolving credit facility||(32,519)||(31,653)|
|Corporate accruals and other payables||(3,410)||(3,222)|
|Current and deferred tax liabilities||(24,950)||(27,961)|
|Revenue by product category||Restated*|
|Third party manufacturing||19,699||18,002|
|Additions to intangible non-current assets by segment (including through business combinations)|
|Pharmaceuticals Research and Development||422||1,065|
|Corporate and central costs||454||25|
*The prior year categorisation has been restated to reflect the current portfolio, following a product allocation review in the period.
|Additions to Property, Plant and Equipment by segment (including through business combinations)|
|Pharmaceuticals Research and Development||102||55|
|Corporate and central costs||77||26|
|Depreciation and amortisation by segment|
|Pharmaceuticals Research and Development||497||816|
|Corporate and central costs||57||50|
The following table shows revenue based on the geographical location of customers and non-current assets based on the country of domicile of the entity holding the asset:
|Rest of Europe||65,796||123,803||71,918||152,158|
|Rest of World||11,111||—||12,400||—|